Literature DB >> 26122381

Patient and treatment factors associated with survival among adult glioblastoma patients: A USA population-based study from 2000-2010.

I-Wen Pan1, Sherise D Ferguson2, Sandi Lam3.   

Abstract

In this study, we utilized the USA surveillance, epidemiology, and end results (SEER) database to examine factors influencing survival of glioblastoma multiforme (GBM) patients. GBM is the most common primary malignant brain tumor in adults and despite advances in treatment, prognosis remains poor. Using the SEER database, we defined a cohort of adult patients for the years 2000-2009 with confirmed GBM and minimum follow-up of 12 months. A total of 14,675 patients with GBM met the inclusion criteria. Demographic, clinical, and treatment variables were examined. Death was the primary outcome. Median survival time was 11 months. Patients had increasingly longer survival over the decade span. We found, on multivariate analysis, that significantly worse survival was associated with age >75 years, male sex, unmarried status, and non-Hispanic Caucasian race/ethnicity. Patients in the Northeast had a significantly lower risk of mortality. Patients with tumors that were non-lateralized and >3 cm fared worse. Patients who did not receive adjuvant radiation also had worse outcomes. Gross total resection imparted a survival advantage for patients compared to biopsy or partial resection. Thus, this report adds to the growing body of literature supporting the positive role of maximal resection on patient survival.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Extent of resection; Glioblastoma; Survival

Mesh:

Year:  2015        PMID: 26122381     DOI: 10.1016/j.jocn.2015.03.032

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  29 in total

1.  Characteristics and prognostic factors of age-stratified high-grade intracranial glioma patients: A population-based analysis.

Authors:  Yun Sun; Zhi-Yong Xiong; Peng-Fei Yan; Liang-Lei Jiang; Chuan-Sheng Nie; Xuan Wang
Journal:  Bosn J Basic Med Sci       Date:  2019-11-08       Impact factor: 3.363

2.  Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.

Authors:  Benjamin M Ellingson; Lauren E Abrey; Sarah J Nelson; Timothy J Kaufmann; Josep Garcia; Olivier Chinot; Frank Saran; Ryo Nishikawa; Roger Henriksson; Warren P Mason; Wolfgang Wick; Nicholas Butowski; Keith L Ligon; Elizabeth R Gerstner; Howard Colman; John de Groot; Susan Chang; Ingo Mellinghoff; Robert J Young; Brian M Alexander; Rivka Colen; Jennie W Taylor; Isabel Arrillaga-Romany; Arnav Mehta; Raymond Y Huang; Whitney B Pope; David Reardon; Tracy Batchelor; Michael Prados; Evanthia Galanis; Patrick Y Wen; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2018-08-02       Impact factor: 12.300

Review 3.  Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma.

Authors:  Benjamin M Ellingson; Patrick Y Wen; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2018-03-27       Impact factor: 12.300

Review 4.  The effect of race on the prognosis of the glioblastoma patient: a brief review.

Authors:  Nitesh P Patel; Kristopher A Lyon; Jason H Huang
Journal:  Neurol Res       Date:  2019-07-04       Impact factor: 2.448

5.  Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma.

Authors:  Ryan Rhome; Rebecca Fisher; Adília Hormigo; Rahul R Parikh
Journal:  J Neurooncol       Date:  2016-03-12       Impact factor: 4.130

6.  Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis.

Authors:  Justin Sharim; Randy Tashjian; Nima Golzy; Nader Pouratian
Journal:  J Clin Neurosci       Date:  2016-03-09       Impact factor: 1.961

7.  Conditional survival after diagnosis with malignant brain and central nervous system tumor in the United States, 1995-2012.

Authors:  Paul Farah; Rachel Blanda; Courtney Kromer; Quinn T Ostrom; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2016-04-19       Impact factor: 4.130

8.  Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.

Authors:  Benjamin M Ellingson; Lauren E Abrey; Josep Garcia; Olivier Chinot; Wolfgang Wick; Frank Saran; Ryo Nishikawa; Roger Henriksson; Warren P Mason; Robert J Harris; Kevin Leu; Davis C Woodworth; Arnav Mehta; Catalina Raymond; Ararat Chakhoyan; Whitney B Pope; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2018-10-09       Impact factor: 12.300

9.  Dose-painted volumetric modulated arc therapy of high-grade glioma using 3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine positron emission tomography.

Authors:  Robert Kosztyla; Srinivas Raman; Vitali Moiseenko; Stefan A Reinsberg; Brian Toyota; Alan Nichol
Journal:  Br J Radiol       Date:  2019-05-14       Impact factor: 3.039

10.  Ongoing improvements in postoperative survival of glioblastoma in the temozolomide era: a population-based data linkage study.

Authors:  Amy Johnston; Nicola Creighton; Jonathon Parkinson; Eng-Siew Koh; Helen Wheeler; Elizabeth Hovey; Michael Rodriguez; David C Currow
Journal:  Neurooncol Pract       Date:  2019-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.